This announcement is a separate document:
上海市方达律师事务所关于诺诚健华医药有限公司2023年科创板限制性股票激励计划首次授予部分第一个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书
Legal Opinion of Fangda Law Firm, Shanghai regarding the Achievements of the First Vesting Period and Cancellation of Some Restricted Stocks in the 2023 Star Restricted Stock Incentive Plan of Innocare Pharmaceutical Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.